Minocycline Therapy for Management of Adverse Radiation Effects
Status:
Terminated
Trial end date:
2018-05-31
Target enrollment:
Participant gender:
Summary
Stereotactic radiosurgery (SRS) is a well-established treatment for patients with metastatic
brain tumors. Although SRS has a very high tumor growth control these interventions are
associated with adverse radiation effects (ARE) in approximately 15 % of patients. The
traditional approach, and still a mainstay, is the administration of a course of high dose
anti-inflammatory corticosteroids. Currently there are no other effective oral
neuroprotective agents in clinical practice which can improve outcomes of patients with ARE
after radiosurgery for brain metastases.
Minocycline, an antibiotic with a favorable adverse effect profile and pharmacokinetics, has
been shown to have neuroprotective properties in experimental models of a variety of
neurological diseases, as well as in human clinical trials. The investigators propose a
single arm clinical trial, to evaluate the safety and feasibility of minocycline in improving
ARE. This study will recruit 15 patients who will be treated with minocycline (100mg BID) for
3 months. This clinical trial has the potential to prove that minocycline therapy is safe in
this patient population. In addition, positive results will provide preliminary evidence for
its use in an array of radiosurgical indications.